بررسي اثر آنتوم در درمان اختلالات ليپيدهاي سرم

Effects of Anethum on plasma lipid disorders

Background: Lipid disorders have an increasing prevalence with known complications. Anethum was revealed to be useful in animal models, thus, the present study was conducted to determine the effects of Anethum on plasma lipid disorders in Shahrekord clinics in 1999. Materials and methods: One hundred one hyperlipidemic patients have enrolled in this clinical trial. Triglyceride, cholesterol, LDL and HDL were determined and patients were randomly distributed in two groups of Anethum and placebo. The first group received Anethum (Baridj Essence, Iran) for 21 days. whereas the second group was given placebo with the same dosage and duration. Following the trial. plasma lipid determinants were evaluated and analyzed. Results: Of 101 patients, 52 were studied in the Anethum group and the remaining 49 were in the placebo group. Groups were matched according to the sex, age, and primary lipid profile. in the Anethum group cholesterol was reduced from 193+37 to 171±36mg/dl (p<0.00 I), but in the control group it was changed from 184+36 to 186+32mg/d1 (NS). Meanwhile, Anethum group has shown a significant reduction in TG level (266+85 to 226±134mgldl, p<0.05) and LDL-C (101+34 to 79±35mgldl, p<0.001). Conclusion: Anethum is an effective agent on plasma lipid disorders. Since it is an available drug with least side effects and expenses, it is highly recommended.